Thrombin (n = 6) | (% ± SEM) | PAR1-AP (n = 6) | (% ± SEM) | PAR-1 Antagonist (n = 6) | (% ± SEM) | (P Value) |
---|
0.5 U/ml
| #28.90 ± 2.60 |
10
-9
M
| *23.91 ± 5.64 |
10
-9
M
| 2.83 ± 3.05 (NS) | (0.630) |
1 U/ml
| *35.39 ± 3.91 |
10
-8
M
| *37.32 ± 2.29 |
10
-8
M
| 3.80 ± 2.33 (NS) | (0.471) |
2 U/ml
| *44.72 ± 2.31 |
10
-7
M
| *52.39 ± 1.28 |
10
-7
M
| 5.60 ± 3.74 (NS) | (0.228) |
3 U/ml
| *53.51 ± 4.62 |
10
-6
M
| *61.50 ± 1.43 |
10
-6
M
| 7.03 ± 5.74 (NS) | (0.148) |
 |  |  |  |
10
-5
M
| 6.87 ± 4.48 (NS) | (0.815) |
- Values presented represent the mean inhibitory effects on umbilical artery tone i.e. after adjusting for control / vehicle experiments. The values provided represent % inhibition ± standard error of the mean (SEM). The PAR1-AP used was Threonine-Phenylalanine-Leucine-leucine-Arginine-NH2. The PAR-1 antagonist used was Ser- pFPhe-pGPe-Leu-Arg-Orn-NH2. The values were compared with amplitude measurements observed prior to drug addition (NS not significant, # P < 0.01, * P < 0.001).